| Genomic hallmarks of localized, non-indolent prostate cancer M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ... Nature 541 (7637), 359-364, 2017 | 603 | 2017 |
| Molecular landmarks of tumor hypoxia across cancer types V Bhandari, C Hoey, LY Liu, E Lalonde, J Ray, J Livingstone, R Lesurf, ... Nature genetics 51 (2), 308-318, 2019 | 534 | 2019 |
| Spatial genomic heterogeneity within localized, multifocal prostate cancer PC Boutros, M Fraser, NJ Harding, R De Borja, D Trudel, E Lalonde, ... Nature genetics 47 (7), 736-745, 2015 | 526 | 2015 |
| What can exome sequencing do for you? J Majewski, J Schwartzentruber, E Lalonde, A Montpetit, N Jabado Journal of medical genetics 48 (9), 580-589, 2011 | 508 | 2011 |
| Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ... The lancet oncology 15 (13), 1521-1532, 2014 | 379 | 2014 |
| The evolutionary landscape of localized prostate cancers drives clinical aggression SMG Espiritu, LY Liu, Y Rubanova, V Bhandari, EM Holgersen, LM Szyca, ... Cell 173 (4), 1003-1013. e15, 2018 | 233 | 2018 |
| A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies MLK Chua, W Lo, M Pintilie, J Murgic, E Lalonde, V Bhandari, ... European urology 72 (5), 665-674, 2017 | 177 | 2017 |
| RNA sequencing reveals the role of splicing polymorphisms in regulating human gene expression E Lalonde, KCH Ha, Z Wang, A Bemmo, CL Kleinman, T Kwan, ... Genome research 21 (4), 545-554, 2011 | 156 | 2011 |
| Unexpected allelic heterogeneity and spectrum of mutations in Fowler syndrome revealed by next‐generation exome sequencing E Lalonde, S Albrecht, KCH Ha, K Jacob, N Bolduc, C Polychronakos, ... Human mutation 31 (8), 918-923, 2010 | 152 | 2010 |
| Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations R Böttcher, CF Kweldam, J Livingstone, E Lalonde, TN Yamaguchi, ... BMC cancer 18, 1-11, 2018 | 125 | 2018 |
| BPG: Seamless, automated and interactive visualization of scientific data C P’ng, J Green, LC Chong, D Waggott, SD Prokopec, M Shamsi, ... BMC bioinformatics 20, 1-5, 2019 | 89 | 2019 |
| Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease GI Allen, N Amoroso, C Anghel, V Balagurusamy, CJ Bare, D Beaton, ... Alzheimer's & Dementia 12 (6), 645-653, 2016 | 86 | 2016 |
| Familial rhabdoid tumour 'avant la lettre'—from pathology review to exome sequencing and back again L Witkowski, E Lalonde, J Zhang, S Albrecht, N Hamel, L Cavallone, ... The Journal of pathology 231 (1), 35-43, 2013 | 86 | 2013 |
| An RMND1 Mutation causes encephalopathy associated with multiple oxidative phosphorylation complex deficiencies and a mitochondrial translation defect A Janer, H Antonicka, E Lalonde, T Nishimura, F Sasarman, GK Brown, ... The American Journal of Human Genetics 91 (4), 737-743, 2012 | 77 | 2012 |
| Mutations in SCARF2 are responsible for Van Den Ende-Gupta syndrome N Anastasio, T Ben-Omran, A Teebi, KCH Ha, E Lalonde, R Ali, ... The American Journal of Human Genetics 87 (4), 553-559, 2010 | 70 | 2010 |
| Epigenetic markers of prostate cancer in plasma circulating DNA R Cortese, A Kwan, E Lalonde, O Bryzgunova, A Bondar, Y Wu, ... Human molecular genetics 21 (16), 3619-3631, 2012 | 65 | 2012 |
| PRiMeUM: a model for predicting risk of metastasis in uveal melanoma J Vaquero-Garcia, E Lalonde, KG Ewens, J Ebrahimzadeh, ... Investigative ophthalmology & visual science 58 (10), 4096-4105, 2017 | 63 | 2017 |
| Genomic diagnosis for pediatric disorders: revolution and evolution E Lalonde, S Rentas, F Lin, MC Dulik, CM Skraban, NB Spinner Frontiers in Pediatrics 8, 373, 2020 | 60 | 2020 |
| Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma KG Ewens, E Lalonde, J Richards-Yutz, CL Shields, A Ganguly BMC cancer 18, 1-12, 2018 | 52 | 2018 |
| Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors E Lalonde, R Alkallas, MLK Chua, M Fraser, S Haider, A Meng, J Zheng, ... European urology 72 (1), 22-31, 2017 | 52 | 2017 |
